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3Abstract (246 words)
Background: Data on viral suppression and adherence patterns of anti-retroviral 
therapy (ART) naïve HIV positive female sex workers (FSWs) initiated on the 
Tenofovir/lamivudine/Efavirenz (TDF/3TC/EFV) fixed dose combination are scarce in 
Zimbabwe. The objectives of this study were to describe the prevalence of and 
factors associated with unsuppressed viraemia as well as the mean adherence of 
FSWs on the Efavirenz based fixed dose tablet after 6 months of treatment. 
Methods: A retrospective record review was done on 77 FSWs who had been 
initiated on TDF/3TC/EFV and had a 6 months post initiation viral load test result at 2 
FSW clinics in Gwanda and Bulawayo, Zimbabwe. Recruitment into the clinics was 
done between July 2013 and September 2015. Data on monthly adherence per pill 
count, 6 months viral load test result and possible predictors of unsuppressed 
viraemia were collected.
Results:  Prevalence of unsuppressed viraemia after 6 months on TDF/3TC/EFV 
FDC tablet was 7.78% (95%CI, 1.67-13.92 %) while viral suppression occurred in 
92.22% (95%CI 83.8-97.1%). Based on the 35 patients with complete adherence 
data, the mean adherence was 99.69% (95%CI, 99.48%-99.91%). All 35 had 
adherence >95% classified as good. Only comorbidity (Adjusted OR 23.31, 95%CI 
Stellenbosch University  https://scholar.sun.ac.za
41.74-310.65, p = 0.017) and baseline CD4 count (Adjusted OR 0.9886; 95%CI 
0.9774-0.9998, p= 0.047) showed independent associations with unsuppressed 
viraemia.
Conclusion: In the first 6 months on TDF/3TC/EFV, ART there is a low prevalence 
of unsuppressed viraemia, high viral suppression rates and high adherence rates in 
naïve HIV positive FSWs in our setting. 
Acknowledgements
I would like to thank my supervisor Tonya Esterhuizen for the guidance throughout 
the process of this study as well as Tawanda Chivese for his help with data analysis 
and write-up. I would also like to thank the management of PSI-Zimbabwe for 
allowing me access to their electronic patient record management system at the 
Gwanda and Bulawayo clinics.
Stellenbosch University  https://scholar.sun.ac.za
5List of figures
Figure 1: Flow chart for enrolment…………………………………………………8
List of tables
Table 1: Demographic and clinical characteristics ………………………………7
Table 2: Factors tested for association with unsuppressed viraemia- univariate 
associations………………………………………………………………………...10
Table 3: Final multivariate logistic regression model ………………………….11
List of abbreviations
ART – Anti-Retroviral Therapy
EFV- Efavirenz
FDC- Fixed dose combination
FSWs- Female sex workers
HIV – Human Immuno-deficiency Virus
PCR – Polymerase Chain Reaction
PSI – Population Services International
OR – Odds Ratio
RNA – Ribonucleic Acid
TDF- Tenofovir
WHO – World Health Organization
3TC – Lamivudine
95% CI – 95% Confidence Interval
 
Key Words
Female sex workers, fixed dose combination, anti-retroviral therapy, HIV, adherence, 
viral load, Zimbabwe
Stellenbosch University  https://scholar.sun.ac.za
6Stellenbosch University  https://scholar.sun.ac.za
1Background
According to WHO, the global prevalence and incidence of HIV is generally declining 
but remains disproportionately high in some population sub-groups termed ‘key 
populations’ in view of their behaviour related increased risk 1. These include sex 
workers, prisoners, intravenous injection drug users, men who have sex with men 
and the transgender community1. Prevalence in these groups still resembles the high 
rates found at the inception of the epidemic before major roll outs of treatment and 
prevention programs. This suggests that these special groups have generally not 
received enough attention in such programs. In Zimbabwe the estimated HIV 
prevalence in sex workers is between 50 and 70% compared to 15% in the general 
population 2. Of all new HIV infections worldwide, between 40 to 50% are occurring 
in key populations 3. It is from such observations that the WHO recognised that if the 
goal of epidemic control by 2030 is to be attained; key populations need to be 
addressed 3. 
Evidence points out to reduction in HIV transmission in sex workers and their clients 
with focused, targeted interventions that include treatment with highly active 
antiretroviral drugs (HAART) commonly known as treatment for prevention2,4, 5,. This 
evidence, recognition by international key stakeholders and the recent WHO 
Guidelines has resulted in a huge global scale up of HIV prevention and treatment 
interventions in sex workers. WHO recommends that HIV positive sex workers 
receive the same antiretroviral therapy management as the general population 1. It is 
also recommended that the single tablet per day fixed dose combination (FDC) of 
Tenofovir, Lamivudine and Efavirenz (TDF/3TC/EFV) be used as it reduces pill 
burden and improves adherence 1. The current guidelines and practice are based on 
evidence from the general population, and the assumption that the improved 
adherence that results from the Efavirenz based FDC’s reduction in pill burden will 
do the same in FSWs. This may not necessarily be true given fundamental 
differences that may exist between the general population and female sex workers 
(FSW) e.g. sleep/work times that make generalizability questionable.
 The study sought to interrogate the FDC use in FSWs by answering the initial key 
questions surrounding viral suppression and adherence in this key population group. 
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2Key pre-antiretroviral therapy counselling messages include use before sleep for 
better tolerance of side effects 1. While it is known that Efavirenz causes 
neuropsychiatric side effects including confusion, sleep disturbances, dizziness and 
vivid dreams, it was not known whether these were a barrier to adherence in sex 
workers 6, . In fact there is a general lack of data on FSWs adherence patterns while 
a lack of access to healthcare could be a significant barrier in HIV control efforts in 
this key population group 7, 8. Our study was in response to calls for researchers to 
investigate issues around adherence in key populations9.The purpose of this study 
was to describe the prevalence of and factors associated with unsuppressed 
viraemia in FSWs on the Efavirenz based fixed dose combination pill after 6 months 
of treatment. Since there have been concerns about poor adherence in sex workers 
particularly those that use recreational drugs, we also sought to describe their 
adherence to the FDC 10. Poor adherence to treatment could lead to unsuppressed 
viraemia, virologic treatment failure and hence high infectivity as well as the risk of 
spreading drug resistant strains of the HIV virus. Drug resistance against a 
background of high baseline prevalence in this key population group could be 
disastrous if the high prevalence translates to high prevalence of resistant strain. 
This would be of significant public health concern since second line antiretroviral 
drugs are very expensive and the cost of managing morbidity in people with resistant 
virus would be much higher . We explored possible predictors to unsuppressed 
viremia in this group including poor adherence, baseline characteristics, report of 
neuropsychiatric side effects and alcohol/substance abuse.
Research Question
What are the prevalence and predictors of unsuppressed viraemia after 6 months of 
treatment on the Efavirenz based fixed dose combination Antiretroviral Therapy in 
HIV positive adult female sex workers in the PSI-Zimbabwe cohort?
Aims and Objectives
The aim of the study was to improve understanding of the burden of unsuppressed 
viraemia and its predictors in early EFV based FDC antiretroviral treatment of female 
sex workers. The primary objective was to estimate the prevalence of unsuppressed 
viraemia in HIV positive female sex workers on Tenofovir/lamivudine/Efavirenz 
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3(TDF/3TC/EFV) single tablet a day fixed dose combination after 6 months of 
treatment. Secondary objectives were to describe the mean adherence of the 
Population Services International (PSI)-Zimbabwe sex worker cohort over 6 months 
and to determine factors associated with poor viral suppression in sex workers on 
the tablet.
Methods
Study Design
We conducted a retrospective record review of routine adherence data recorded 
monthly and HIV viral load results measured at 6 months after initiation of the EFV 
based FDC. The study was conducted at PSI-Zimbabwe sex worker clinics in the 
Zimbabwean towns of Gwanda and Bulawayo. The participants had been enrolled 
on to the clinics’ Anti-Retroviral Therapy program from July 2013 for the Bulawayo 
clinic and July 2014 for the Gwanda clinic up to September 2015. Data collection 
was done from 22/10/2015 to 06/11/2015.
Study Population and Sampling
The target population was HIV positive female sex workers in Gwanda and 
Bulawayo. The target population is hard to reach, specific and limited in availability 
hence we preferred a record review. Attendees to the sex worker clinics were 
assumed to be representative of the HIV positive sex worker population in 
Zimbabwean towns and presenting in random order. Recruitment into the ART 
program at the clinic was open to all FSW of all ages. Most would have come as 
walk-ins mobilised at hot spots such as brothels and night clubs while some came as 
referrals from partner organizations dealing with FSWs. All HIV positive treatment 
naïve FSWs over the age of 18 years being initiated on the FDC tablet at the clinics 
with a 6 months post initiation HIV viral load result were eligible. 176 were potentially 
eligible by virtue of being on the FDC for more than 6 months and all had an HIV 
viral load blood sample taken since this is routine. However, 99 did not have an HIV 
viral load result by the end of data collection due to huge backlogs with the 
laboratory. As such, a total of 77 records, 18 from Gwanda and 59 from Bulawayo 
clinics were found to be eligible (see figure 1). 
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4Measurements
The HIV viral load results and adherence data were obtained as routine data from 
EpocWeb, an electronic patient file management system used at the clinics. Patient 
HIV viral loads were measured routinely at 6 months of treatment at Newlands clinic 
laboratory in Harare using HIV RNA PCR based COBAS Ampliprep/Taqman 48. 
Replicates for HIV negative, low positive and high positive controls were included in 
each batch for quality assurance. Percentage adherence were calculated by nurses 
using pill counts against dispensed number of tablets monthly and imputed onto 
EpocWeb. Where complete data were available, the mean adherence for each 
patient was calculated as the average monthly adherence for the 6 months. Reports 
of neuropsychiatric illness, comorbidities and opportunistic infection were obtained 
on the diagnoses section while that of alcohol use and recreational drug use were 
found on the history section. 
Data Management 
Data collected
Data collected included HIV viral load, classified as suppressed when it is less than 
1000 copies per ml, and monthly percentage adherence which was documented on 
visits in the patient electronic record. The calculated 6 months mean adherence was 
classified as good when greater than or equal to 95% or poor when less than 95%. 
Other data collected include age, clinical stage at ART initiation, baseline CD4 count, 
presence of incomplete 6 months  adherence data, report on adverse events during 
treatment, presence of co-morbidities, occurrence of opportunistic infections, alcohol 
use status (alcoholic/non-alcoholic) and recreational drug use.
Data Collection Procedures
Data were collected retrospectively directly from queries run on Epoc Web and 
manually captured onto the patient’s data collection form identified only by a unique 
study ID with no meaning external to the study. The data collected on the forms was 
then electronically captured into an Excel spread sheet data extraction form. 
See Appendix A for the data capture form and coding used. 
Statistical Analysis 
This study had 2 components. The descriptive component aimed to assess the 
extent of the burden of unsuppressed viraemia and the mean adherence in FSWs. 
Stellenbosch University  https://scholar.sun.ac.za
5The analytical component aimed to identify risk factors for poor virological 
suppression in FSWs. In determining the sample size, the study aimed to estimate 
the prevalence of unsuppressed viraemia with a precision of +/- 5%. Some studies 
have estimated the prevalence at between 5-15% in the general population 11. We 
expected it to be around 10% in our cohort. Allowing for 10% missing data the 
required sample size was calculated at 153 participants.  Only 77 meeting inclusion 
criteria due to time constraints were identified, which resulted in only a small loss of 
precision. Statistical analysis was done using Stata version 13 12. The prevalence of 
unsuppressed viraemia was calculated as a proportion with a 95% confidence 
interval and the mean adherence was calculated as a percentage with its standard 
deviation, and 95% confidence interval. 
Associations between categorical risk factors (clinical stage, incomplete adherence 
data, neuro-psychiatric side effects, and presence of co-morbidity, opportunistic 
infections, alcohol use and recreational drug use) and the outcome of unsuppressed 
viraemia were assessed using Pearson’s chi square tests. Wilcoxon rank-sum test 
was used to compare mean adherence, age, and baseline CD4 count between the 
participants with and without suppression. Factors and covariates identified as 
associated with unsuppressed viraemia at the 0.1 level of significance on univariate 
analysis were entered as independent variables in a binary logistic regression 
analysis in order to ascertain odds ratios and 95% confidence intervals for 
independent risk factors for the outcome. The final model was arrived at using 
backward elimination with entry and exit probabilities set at 0.1 and 0.05 
respectively. 
Results
Characteristics of participants
Table 1 shows the demographic and clinical characteristics for the participants 
included in the study. A total of 77 patients who were anti-retroviral therapy (ART) 
naïve, then initiated and kept on the Tenofovir/lamivudine/Efavirenz fixed dose 
combination tablet and had an HIV viral load result at 6 months on treatment’s 
records were reviewed. 18were from Gwanda and 59 were from the Bulawayo clinic. 
Figure 1 shows the flowchart for enrolment with details of the potentially eligible to 
the final total used for analysis after application of the eligibility criteria. The median 
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6age was 31 (IQR, 26-35) years. At ART initiation the median CD4 was 282 (IQR, 
153-348) cells/dl. Of the 75 who had WHO clinical staging data 47.37% were stage 
1, 22.37% were stage 2, 23.68% were 3 and 6.58% were stage 4. Only 35 patients 
had complete adherence data. Of these, all had good 6 months mean adherence 
above 95% per pill count. None of the 77 patients had evidence of reporting 
neuropsychiatric side effects of Efavirenz in the records. Thirteen (16.88%) had 
comorbidities of which 5 (38.46%) had Iron deficiency anaemia, 6 (46.15%) had 
anaemia of chronic illness and 2 (15.38%) had hypertension. 4 out of the 6 (66.67%) 
unsuppressed clients had an anaemia of chronic illness diagnosiss, 1 had Iron 
deficiency anaemia while 1 had no comorbidity. Nine (11.69%) were diagnosed with 
opportunistic infections of which 7 (77.78%) had oral candidiasis while 2 (22.22%) 
had oesophageal candidiasis. Data on alcohol and recreational drug use was found 
in only 20 records of which 12 (60%) reported alcohol use, and none reported 
recreational drug use.
Prevalence of unsuppressed viraemia
All participants in the study had an HIV viral load result recorded after 6 months of 
treatment. The prevalence of unsuppressed viraemia after 6 months on 
TDF/3TC/EFV FDC tablet was 7.78% (95%CI, 1.67-13.92 %). Viral suppression rate 
in this sex worker population was estimated at 92.22% (95%CI, 86.08-98.33%).
Table 1: Demographic and clinical characteristics (N =77)
Characteristic Result
Age (median, IQR) years 31      (26,35)        
*Mean Adherence 
(median, IQR) % 
99.7   (99.5-99.9)
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7Baseline CD4 count 
(Median, IQR) cells/dl
282      (153-348)
*Adherence, no. (% with complete 
data)
Good   35 (100)
Poor      0
HIV viral load, no. % Suppressed <1000c/ml 71 (92.22)
Unsuppressed >1000c/ml   6 ( 7.78)
Opportunistic infections no. %
Total 9 (11.69)
Oral candidiasis   7 (9.09)
Oesophageal candidiasis   2 (2.6)
Comorbidity, no. %
Total 13 (16.88)
Iron deficiency anaemia   5 (6.49)
Anaemia of chronic illness   6 (7.79)
Hypertension   2 (2.6)
‡Alcohol, no. (% with complete 
data)
Users  12( 60)
Non-users    8 (40)
*incomplete data, only 35 participants out of 77 had complete 6 months adherence data
‡ Only 20 participants had documented data on alcohol intake 
Not recorded for recreational drug use
Stellenbosch University  https://scholar.sun.ac.za
8   GWANDA CLINIC                                                              BULAWAYO CLINIC
Figure 1: Flow Chart for enrolment 
Stellenbosch University  https://scholar.sun.ac.za
9Mean adherence
For the first 6 months after ART initiation, based on the 35 patients with complete 
adherence data the mean adherence was 99.69% (95%CI, 99.48%-99.91%). All 35 
had adherence >95% classified as good per pill count. 42 patients (54.55%) had 
incomplete 6 months adherence data.
Factors associated with unsuppressed viraemia in female sex workers
On univariate analysis, baseline CD4 count showed a statistically significant 
association with unsuppressed viraemia (OR 0.989, 95%CI 0.977-0.9998, p= 0.001 
while age and mean adherence were not associated (see Table 2). Incomplete 6 
months adherence data, neuropsychiatric side effects, type of comorbidity, alcohol 
use and recreational drug did not show any statistically significant association with 
unsuppressed viraemia. Presence of an opportunistic infection showed a weak 
association with a p-value of 0.086 while presence of a comorbidity (p<0.001) 
showed strong association with unsuppressed viraemia. Clinical stage (p= 0.001) 
showed a statistically significant association and more advanced disease (stage 
3&4) showing an even stronger association with a p<0.001.Clinical stage could not 
be included in the logistic regression analysis due to 100% of the unsuppressed 
patients being in stage 3 or 4. 
Further analysis with logistic regression modeling was done on baseline CD4 count, 
presence of co-morbidity and presence of an opportunistic infection (see table 3). 
Presence of a comorbidity had a statistically significant association with an adjusted 
OR of 23.308 (95%CI, 1.75-310.65, p=0.017). Baseline CD4 count had a weak 
association with an adjusted odds ratio (OR) of 0.989 (95%CI, 0.9774-0.9998). 
There was a non-statistically significant association between the presence of 
opportunistic infection and unsuppressed viraemia, with the adjusted OR 4.34 
(95%CI, 0.25-73.98, p=0.310). 
Table 2: Factors tested for association with unsuppressed viraemia- univariate 
associations
Variable           Overall Result    Suppressed    Unsuppressed  OR (95% CI)    P value
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Age, Median 
(IQR) years
31 (26,36) 31 (26,35) 34.5 (22,39) 0.607
Baseline CD4, 
Median (IQR) 
cells/ml
282 
(153,348)
289(187,350) 51.5 (21,100) 0.984 
(0.973-
0.996)
0.007
Mean 
adherence, 
mean (95%CI) 
%
99.7 (99.5-
99.9)
99.64 
(99.5,100)
100 (100,100) 0.167
Incomplete 
adherence data, 
number (%)
42 (54.55) 41 (57.75) 1 (16.67) 0.146 
(0.163-
1.318)
0.087
Advanced 
Clinical stage 
3&4, number 
(%)
23 (30.26) 17 (24.29) 6 (100) <0.001
Comorbidity, 
number (%)
13 (16.88) 8 (11.27) 5 (83.33) 39.375 
(4.070-
380.959)
<0.001
Comorbidity type
Iron deficiency 
anemia
Anemia of 
chronic illness
Hypertension
number (%)
5
6
2
4 (5.63)
2 (2.82)
2 (2.82)
1 (16.67)
4 (66.67)
1.108 
(0.223-
5.498)
0.9
Opportunistic 
infections, 
number (%)
9 (11.69) 7 (9.86) 2 (33.33) 4.570 
(0.710-
29.610)
0.086
Neuropsychiatric 
side effects
0 0 0
Alcohol use, 
number (%)
12 (60) 11 (57.89) 1 (100) 0.402
Recreational           0                     0                       0
drug use
Table 3: Final multivariate logistic regression model
Factor Adjusted OR (95% CI) P-value
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Comorbidity 23.308 (1.749-310.646) 0.017
Baseline CD4 0.9886 (0.9774-0.9998) 0.047
Discussion
Our study estimated the prevalence of unsuppressed viraemia in the PSI-Zimbabwe 
FSW cohort on the FDC TDF/3TC/EFV tablet to be 7.78% after the first 6 months of 
treatment. Most of the participants, 92.22%, had viral suppression, a figure that is 
above the WHO targets of having at-least 90% of all clients on ART suppressed by 
2020. These estimates are above those given in other studies for anti-retroviral 
therapy in general. A study in Burundi reported that 81.8% of FSWs had 
undetectable viral load results 13. A recent systematic review that included studies 
from 21 different sex worker populations in Africa, Asia, South and Central America 
and the Caribbean gave pooled estimates of 57% (95% CI:46-68%) achieving viral 
suppression 14. All the 35 participants with complete adherence data had good 
adherence measured as >95% adherence per pill count. The mean adherence was 
very high at 99.69%.  These figures are biased upwards since non-compliant 
patients are more likely not to have complete adherence data; however the impact of 
this bias is minimal given that the more objective measure of HIV viral load showed 
high suppression rates. Furthermore, of those with good adherence, 14% (5/35) 
were unsuppressed, compared with the 7.8% of the total cohort. Thus it appears that 
the possible bias was minimal.  Our study is the first to give such data on the sex 
worker population on an Efavirenz based regimen in Zimbabwe. Our estimates are 
higher than the 55.5% observed in a Canadian study where concerns were raised 
about suboptimal adherence (on ART in general) in the sex worker population 10. 
The low prevalence of unsuppressed viraemia, and high adherence levels should 
encourage clinicians to scale up TDF/3TC/EFV roll out in FSW populations in 
Zimbabwe and similar settings. No neuropsychiatric side effects of efavirenz were 
reported in this study. An advanced clinical stage (3 & 4), low baseline CD4 count 
and the presence of a comorbid condition were all independently associated with 
unsuppressed viraemia. Larger studies in similar settings may be considered to 
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investigate other predictors and to explore further those studied (but may have had 
small differences missed due the small sized nature of our study). Since high 
adherence levels were observed even in those that were unsuppressed, concerns 
for transmitted resistance need to be raised 15. As such, patients with these 
independent predictors may be considered for HIV resistance testing before ART 
initiation. They would then be initiated on sensitive drugs to minimize the risk of the 
virus acquiring more mutations and developing resistance to multiple drugs. Further 
studies to determine the utility of drug sensitivity testing in FSWs with these 
predictors in resource poor settings such as the one in which our study was carried 
out need to be done.  
The study had limitations that need to be considered in the interpretation of findings. 
The study sample was small, reducing the power and hence the ability to detect 
small differences in the variables. Though there were many FSWs who could have 
been on TDF/3TC/EFV for more than 6 months, not many had a 6 months HIV viral 
load result  due to poor turnover, huge backlogs and delays in processing specimens 
at the out-sourced laboratory. Bias may have been introduced as patients clinically 
or immunologically failing are more likely to have their viral load results followed up 
with the laboratory and hence more likely to be included in the study yet they are 
more likely unsuppressed. However the effect of their inclusion would have been to 
increase the prevalence of unsuppressed viraemia and decrease the viral 
suppression rates when in fact the study showed a low estimate for the prevalence 
and a high viral suppression rate thereby increasing the validity of the study 
estimates.  There needs to be an increase in efforts to increase the turnover of viral 
load results in Zimbabwe. 
The precision of our estimates was affected by the small sample size for the 
association of comorbidity and unsuppressed viraemia which had statistically 
significant odds ratio of 23.31 but a very wide confidence interval of 1.75 to 310.65. 
Prevalence of unsuppressed viraemia, mean adherence and baseline Cd4 counts 
estimates were reasonably precise. Since we used an observational study design, 
confounding could only be controlled for to an extent in the analysis of the data; 
hence findings need to be interpreted with caution as other unmeasured factors may 
have influenced the results. There was also a major challenge with missing data 
particularly for adherence, alcohol and recreational drug use. Using pill count as a 
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measure of adherence is easily prone to manipulation by the patient, the impact of 
this was however likely minimal since there was satisfactory viral suppression. 
Data on the prevalence of unsuppressed viraemia and factors associated with it in 
FSWs within the Zimbabwean context are scarce 14. This study formed an important 
first step to addressing concerns such as the question of suitability of an Efavirenz 
based regimen in sex workers that may be a barrier holding back healthcare 
providers from scaling up treatment roll out. Our study suggests that it is suitable to 
use an EFV based regimen in sex workers with low prevalence of unsuppressed 
viraemia after 6 months of use. It also gave early insights into concerns about risk 
and burden of transmitted resistance in the sex worker population in Zimbabwe.  The 
findings of our study will be of importance to government health departments, 
educational institutions and non-governmental institutions in formulating policies and 
coining interventions that are tailor made for this key population group, including the 
development of group specific messages. 
Conclusion
In the first 6 months on TDF/3TC/EFV, ART naïve HIV positive FSWs showed a low 
prevalence of unsuppressed viraemia, and high adherence rates. Policy makers and 
clinicians should be encouraged to roll out this FDC pill to FSW. FSWs with 
advanced HIV disease, comorbidity and low baseline CD4 counts should be watched 
closely for poor viral suppression. Though further studies are needed, drug 
sensitivity testing could be considered before ART initiation in HIV positive FSWs 
with these possible predictors.
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Appendix 1: Data collection form
Date of data collection  
PROJECT S15/07/144, Incidence of unsuppressed viraemia in HIV positive sex workers on 
the daily single dose TDF/3TC/EFV tablet for 6 months: PSI-Zimbabwe sex worker cohort
PART A
Study ID                                                        
Study Site       Tick one box
1. Bulawayo
2. Chivhu
3. Gundu
4. Gwanda
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5. Magunje
6. Kadoma
7. Kariba
Age
6 Months Viral Load tick appropriate box
<1000 Copies per ml (Suppressed)
>1000 Copies per ml (Unsuppressed)
Adherence
Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
6 months Mean Adherence
Overall Adherence tick appropriate
Good Adherence 
Poor Adherence
PART B
WHO Clinical Stage at ART initiation
Baseline CD4 Count
Report of Neuropsychiatric Side Effects  tick appropriate
Yes    
No     
Nature of Neuropsychiatric Side Effects tick appropriately  
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Drowsiness 
Insomnia
Nightmares/vivid dreams
Confusion
Memory loss
Hallucinations
Delusions
Depression
Other `                   
Describe…………………………………………………………………...
Alcohol use 
Yes                    No    
Alcoholic by CAGE Score
Yes                     No                 
Inadequate information in records to classify 
Recreational Drug Use
Yes                    No
Type of recreational drug used…………………………………………………………………… 
Presence of Opportunistic Infections
Yes                     No   
Type of Opportunistic 
infection………………………………………………………………………………….
Co-morbidities
Yes                    No
Nature of Co-morbidity
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Appendix 2: Ethics Clearance
Request for Modifications
New Application
11-Aug-2015
Moyo, Brian BK
Ethics Reference #: S15/07/144
Incidence of unsuppressed viraemia in HIV positive sex workers on the daily single 
dose TDF/3TC/EFV tablet for 6 Title: months: PSI-Zimbabwe sex worker cohort.
Dear Dr Brian Moyo,
The New Application received on 06-Jul-2015, was reviewed by members of Health Research Ethics Committee 2 
via Expedited review procedures on 07-Aug-2015.
In principle the Committee is in agreement with the project, but requested that you should attend to the following matters 
before the project could be finally approved. The following modification(s) and/or additional information about the 
research or the application are requested:
1. Our HREC can grant a waiver of informed consent on the condition that the data is completely anonymised 
i.e. even the investigators should not be able to link the study codes back to any patient. Kindly revise in the 
protocol and resubmit. Please also submit a copy of your data collection sheet for review.
On receipt of the additional information / corrected document(s) the application will be reconsidered.
Please provide a letter of response to all the points raised IN ADDITION to HIGHLIGHTING or using TRACK CHANGES 
function indicate ALL corrections / amendments of ALL DOCUMENTATION, clearly in order to allow rapid scrutiny and 
appraisal.
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The HREC has determined that your response to this Request for Modifications may be reviewed via Expedited review 
procedures. Based on your response the HREC has the prerogative and authority to ask further questions, seek 
additional information, require further modifications, or refer your response to the convened HREC.
Please note that the application for approval and registration of this project would be cancelled automatically if no 
feedback is received from you within 6 (six) months of the date of this letter.
Please note that you may not recruit subjects until you receive a written notice of HREC approval that will include the 
date-stamped informed consent document(s) to use when seeking consent from subjects.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
If you have any questions or need further assistance, please contact the HREC office at 219389207.
Sincerely,
Mertrude Davids
HREC Coordinator
Health Research Ethics Committee
Appendix 3: Ethics Amendments 
Ethics Letter
20-Oct-2015
 
 
Ethics Reference #: S15/07/144
Title: Incidence of unsuppressed viraemia in HIV positive sex workers on the daily single dose 
TDF/3TC/EFV tablet for 6 months: PSI-Zimbabwe sex worker cohort.
 
Dear Dr Brian Moyo,
 
The Health Research Ethics Committee approved the amended documentation:
Amendment #1, dated 29 September 2015 - substitution of a clinic for data collection purposes
 
If you have any queries or need further help, please contact the REC Office 219389819.
 
Sincerely,
 
REC Coordinator
Ashleen Fortuin
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Health Research Ethics Committee 2
SAJID Author Guidelines
Manuscripts submitted to the SAJID must be in the form of Research Articles, Brief 
Reports, Clinical Case Studies, Correspondence, Reviews, State-of-the-Art Articles, 
Commentaries and Opinion Papers, Editorials or Supplement Articles. The Journal 
welcomes the publication of Guidelines, Conference Proceedings Newsletters or 
Press Releases, and Book Reviews. Articles, Brief reports and Reviews are peer 
reviewed; other categories are reviewed by the Editors. Commentaries and Editorials 
are generally invited contributions, indicating the authors’ identity, while manuscripts 
in the form of Reviews, and State-of-the-Art Articles may also be requested by the 
Editors.
All manuscripts must have conflict of interest and funding statements. When authors 
submit a manuscript, whether an article or a letter, they are responsible for disclosing 
all financial and personal relationships that might bias their work. To prevent 
ambiguity, authors must state explicitly whether potential conflicts do or do not exist. 
Authors should do so in the manuscript on a conflict-of-interest notification page that 
follows the title page. 
Manuscripts describing research in human subjects or animals must indicate 
ethics clearance from appropriate research review committees. When reporting 
experiments on human subjects, authors should indicate whether the procedures 
followed were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2008. When reporting experiments on animals, 
authors should indicate whether the institutional and national guide for the care and 
use of laboratory animals was followed.
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Articles describe original investigations at an acceptable degree of completion, 
constituting an advance in the field. Articles must not exceed 3500 words of text, 
without counting the abstract, references or legends, and illustrations and tables 
must be limited to the minimum necessary for clear and concise presentation. The 
abstract must either be structured, using Background, Methods, Results, and 
Conclusions as headings and comprising no more than 250 words, or unstructured 
with a 200 word limit. Articles are limited to a maximum of 7 insets (tables and 
figures combined) and 50 references.
Brief Reports present complete studies that are narrower in scope than those 
described in Articles or that present new developments. Manuscripts that are 
descriptive or primarily methodological in nature, or that describe in vitro 
chemotherapeutic studies should, in general, be submitted as Brief Reports. Brief 
Reports include an abstract (no more than 100 words) and are limited to a total of no 
more than 2000 words of text, a total of 2 inserts (tables or figures), and 15 
references.
Correspondence (letters) must be submitted in reference to a previous publication in 
SAJID (within the previous 12 months), or relate to a topical matter in line with the 
interests of FIDSSA, PHASA or their affiliated societies. Please prepare the letter in 
manuscript format, including a title page. The letter must not exceed 750 words of 
text, 1 insert (table or figure) and 10 references. 
Commentaries and Editorials are generally invited by the Editor and are overviews of 
articles in SAJID, or of other research in epidemiology or infectious diseases, or 
matters relating to public health and other issues of special interest to FIDSSA, 
PHASA or their associated societies. Unsolicited commentaries are also considered.
Reviews and State-of-the-Art Articles that are research oriented or fall within the 
fields of interests of FIDSSA, PHASA or any of their affiliated societies will be 
considered for publication by SAJID. Prospective authors of such manuscripts are 
advised to communicate with the Editor in advance to ensure that a specific 
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contribution is deemed appropriate and timely. Manuscripts of Reviews and State-of-
the-Art Articles will be peer-reviewed.
Reviewers 
The Journal would encourage authors to supply the names of at least 2 potential 
reviewers for their manuscript, as well as to indicate any reviewers they would feel 
may have a potential conflict of interest with regard to their submission. 
Supplements
Requirements for supplement manuscripts generally follow those for SAJID 
manuscripts, including conflict of interest and funding statements. Inquiries relating 
to suitability of topic, programme organisation, production and costs should be made 
to the Editor.
Evaluation of manuscripts
Review procedure. The Editor-in-Chief and Emeritus Editor screen all unsolicited 
manuscript submissions and some of these are rejected without further review. All 
other manuscripts are sent to a minimum of two outside experts for review. After 
receipt of the reviewers’ reports, the Editor-in-Chief and the Emeritus Editor with 
administrative assistance of the Journal Secretary discuss the merits of the 
manuscripts and the Editor-in-Chief makes the final decision to accept, reject, or 
request revision of the manuscript. A request for revision does not guarantee 
ultimate acceptance of the revised manuscript 
Related manuscripts. If there appears to be significant overlap between a manuscript 
submitted to SAJID and another submitted manuscript by the same authors to SAJID 
or another journal, the editors will take the matter up with the corresponding author, 
and based on the response, take appropriate action (ask for modification, or reject 
with detailed explanation). Further action may include informing the appropriate 
authority in the authors’ resident institution and if overlapping is discovered after 
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publication in SAJID, publishing an appropriate announcement to that effect in the 
journal.
DOCUMENT REQUIREMENTS
Checklist
The following are required for your manuscript to be processed:
 Covering letter
 Word count limits
 Conflict of interest statement
 Funding statement
 List of potential reviewers
Covering Letter
All manuscripts submitted to SAJID must be accompanied by a letter declaring that 
the manuscript has not been submitted or accepted for publication elsewhere. This 
letter must confirm and declare that all authors have seen and approved the content 
and have contributed significantly to the work. Authors should suggest potential 
unbiased reviewers who are qualified to review their manuscript. A covering letter 
must also accompany a revised submission and must address issues raised in the 
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review process.
Manuscript Preparation
The SAJID complies with the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journal Journals (Ann Intern Med 2000; 133:229-231 [editorial]; 
http://www.icmje.org, full text). Text, tables, references, and legends must be 
double- spaced. Italics should be used for genus and species names and for genes 
but not for in vivo, in vitro, in situ, et al., or other Latin-derived expressions. For 
layout of manuscript and appropriate style see a recent issue of SAJID.
Title page. On the title page, please supply a running head of not more than 40 
characters and spaces, a title of not more than 160 characters and spaces, the 
names and affiliations of all the authors, and word counts of the abstract and text. 
Each author’s first name, subsequent initials and surname must be used.
Footnote page. Footnotes must include:
 Statement that authors either have or have not a commercial or other 
association that might pose a conflict of interest (e.g. pharmaceutical stock 
ownership, consultancy, advisory board membership, relevant patents, or 
research funding)
 Statement naming sources of financial support (including grant numbers)
 Name, date (month and year), and location (city, and country if not South 
Africa) of a meeting at which all or part of the information has been presented 
(include an abstract number, if available)
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 Name, address, telephone and fax numbers, and e-mail address of the 
person to whom correspondence should be addressed
 Current affiliations and addresses for authors whose affiliations have changed 
since completion of the study
Abstract. The abstract for an Article may be structured with the headings 
Background, Methods, Results, and Conclusions (250-word limit) or unstructured 
(200-word limit). Abstracts of Brief Reports should be no more than 100 words. 
Whether structured or unstructured, the abstract must state the purpose of the 
research, the methods used, the results, and the conclusions. Do not cite references 
in the abstract. Include up to 10 key words, separate from the abstract. Please 
remember that the abstract is particularly useful for literature retrieval purposes.
Text. The text of Articles must be no longer than 3500 words, and that of Brief 
Reports no longer than 2000 words. The Methods section must include a statement 
that informed consent was obtained from patients or their parents or guardians, and 
human experimentation guidelines of the National Department of Health 
(http://www.doh.gov.za) or the South African Medical Research Council (MRC; 
http://www.sahealthinfo.org/ethics/index.htm) and /or those of the authors’ 
institution(s ) were followed in the conduct of clinical research or that animal 
experimentation guidelines (see MRC website above) were followed in animal 
studies.
References. Articles are generally limited to 50 references, Brief Reports to 15 
references. Only works that have been published or accepted for publication can be 
included in the reference list. Unpublished observations by the authors (authors’ 
unpublished data) personal communications (SP Stanley, personal communication), 
and manuscripts submitted for publication (J Odendaal, S Coovadia and J Radebe, 
submitted) should be mentioned parenthetically in the text Please number references 
in order of appearance; those cited only or first in tables or figures are numbered 
Stellenbosch University  https://scholar.sun.ac.za
26
according to the order in which the table or figure is cited in the text. Example: If 
table 3 is cited in the text after reference 20, a new reference cited in table 3 will be 
reference 21.
References must follow the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals (http://www.icmje.org, full text). Provide all authors’ (or editors’) 
names when there are fewer than 7; for 7 or more, list the first 3 and add “et al.” 
Titles of journals not listed in Index Medicus should be spelt out in full. Reference to 
a doctoral thesis or Master’s dissertation should include the author, title, institution, 
location, year and publication information, if published. For online resources, include 
a URL and date accessed. Accuracy of references is the responsibility of the 
authors. 
Examples of the proper format are as follows:
Sonnenberg P, Glyn Thomas R, Glynn JR, Shearer S, Godfrey-Faussett, Murray J. 
Clinical and radiological features of pulmonary disease due to culture-positive 
Mycobacterium tuberculosis or non-tuberculous mycobacteria in South African gold 
miners. South Afr J Epidemiol Infect 2005; 20: 130-135
Marin M, Nguyen HQ, Langidrik JR, et al. Measles transmission and vaccine 
effectiveness during a large outbreak on a densely populated island: Implications for 
vaccination policy. Clin Infect Dis 2006; 42: 315-319
Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein 
WA, eds. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004: 389-440.
Mothibeli KM, McGee L, Smith AM, Klugman KP. Molecular epidemiology of 
pneumococcal serotype 3 isolates.[abstract ID P56]. In: Programme and Abstract 
Book of the 1st Joint Congress of the Federation of Infectious Diseases Societies of 
Southern Africa (Sun City, North-West Province). Johannesburg: Presentations 
Graphics, 2005: 42.
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World Health Organization. Initiative for vaccine research. Available at: 
http://www.who.int/vaccine_research/diseases/measles/en/. Accessed 1 February 
2005.
Acknowledgment(s). The page preceding the references may include a statement 
thanking those who assisted substantially with work relevant to the study.
Statistical analysis. The statistical analyses used should be identified both in the text 
and in all tables and figures where the results of statistical comparison are shown.
Units of measure. All Data should be expressed in metric units; use of SI units is 
encouraged. Use ºC for temperature.
Tables and figures. Articles are limited to a maximum of seven inserts (tables and 
figures combined), Brief Reports to a maximum of two inserts. Data should not be 
repeated in both a table and a figure. Abbreviations and acronyms used in tables 
and figures must be explained in the table footnotes and figure legends, even if 
already defined in the text.
Tables should be numbered in the order of mention in the text. Tables should be 
typed double-spaced throughout, with no vertical or internal rules. Footnotes and 
accompanying explanatory material should be kept to a minimum. Footnotes should 
be placed below the table and designated by superscript lowercase letters (listed in 
order of location when the table is read horizontally). Each column must have an 
appropriate heading describing the data in the column below, and units of measure 
must be clearly indicated. For further instructions on the preparation of tables in 
Word , consult the Special Instructions for Tables.
Figures should be also numbered in the order of mention in the text and should 
appear at the end of the manuscript and references. Your figures should be prepared 
in accordance with the Guidelines for Submission of Artwork. Letters, numbers, and 
symbols should be clear and of sufficient size to be legible when the figures are 
reduced. Photomicrographs should have internal scale markers. Figures reproduced 
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from other publications must be accompanied by permission from the copyright 
holder. If the manuscript is accepted, the author will be required to send one 
complete set of glossy, hard-copy figures.
Figure legends should be double-spaced and appear on a separate page preceding 
the figures. Any abbreviations or symbols used but not defined in the figure itself 
must be defined in the legend. 
Style. Authors are referred to the American Medical Association Manual of style: A 
Guide for Authors and Editors (9th ed., Williams& Wilkins, 1997) and the Chicago 
Manual of Style (15th ed., University of Chicago Press, 2003).
For commercially obtained products mentioned in the text, list the full names of 
manufacturers. Generic names of drugs and other chemical compounds should be 
used.
Nomenclature. SAJID recommends the latest widely accepted nomenclature, as set 
out in documents prepared by recognised international agencies e.g. the 
International Journal of Systematic and Evolutionary Microbiology, Bergey’s Manual 
of Determinative Bacteriology (9th ed., revised, Williams& Wilkins, 1993), Virus 
Taxonomy – The Classification and Nomenclature of Viruses: Sixth Report of the 
International Committee on Taxonomy of Viruses (Springer-Verlag, 1995). The latter 
document also supplies standard abbreviations for virus species.
Clinical trials registration. All clinical trials must be registered in a registry that is 
electronically accessible to the public, free of charge. Registration should occur 
before patient enrolment and the registry’s URL and the trial’s registration number 
must be supplied at the end of the manuscript’s abstract. For information on 
acceptable registries, consult the ICMJE Web site, http://www.icmje.org . The 
National Library of Medicine’s registry which is free and open to all investigators, 
generally meets with the requirements of journals for the publication of clinical trials.
MANUSCRIPT SUBMISSION
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Procedure
Authors are advised to retain a copy of submitted manuscripts, including tables, 
figures and photomicrographs. The journal is not responsible for manuscripts lost or 
damaged. 
All manuscripts must be submitted online at www.sajei.co.za. Register as an author, 
login in and click on CLICK HERE TO FOLLOW THE FIVE STEP SUBMISSION 
PROCESS. The covering letter must please be submitted as a supplementary file. 
For assistance to upload your manuscript or further instructions please contact Ms 
Robyn Marais at toc@sajei.co.za.
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As part of the submission process, authors are required to check off their 
submission's compliance with all of the following items, and submissions may be 
returned to authors that do not adhere to these guidelines.
1. The submission has not been previously published, nor is it before another 
journal for consideration (or an explanation has been provided in Comments 
to the Editor).
2. The submission file is in Microsoft Word, RTF document file format.
3. Where available, URLs for the references have been provided.
4. The text is one and a half-spaced; uses a 12-point font; employs italics, rather 
than underlining (except with URL addresses); and all illustrations, figures, 
and tables are placed within the text at the appropriate points, rather than at 
the end.
5. The text adheres to the stylistic and bibliographic requirements outlined in the 
Author Guidelines, which is found in About the Journal.
6. The following is required for your manuscript to be processed:
o Covering letter
o Word count limits
o Conflict of interest statement
o Funding statement
o List of potential reviewers
 
Copyright Notice
By submitting manuscripts to SAJID, authors of original articles are assigning 
copyright to the SAJID. Authors may use their own work after publication without 
written permission, provided they acknowledge the original source.
Individuals and academic institutions may freely copy and distribute articles 
Stellenbosch University  https://scholar.sun.ac.za
31
published in SAJID for educational and research purposes without obtaining 
permission.
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